Autolus Therapeutics plc

About Autolus Therapeutics plc

Autolus is a biopharmaceutical company focused on developing advanced autologous T cell therapies, specifically CAR T cell therapies, to deliver life-changing treatments for patients with cancer and autoimmune diseases. The company aims to build a fully integrated, next-generation CAR T company with a commitment to innovation and patient care.

Products & Services

Obecabtagene Autoleucel (obe-cel):A CAR T cell therapy for adults with B-Cell Acute Lymphoblastic Leukemia (ALL), with ongoing development for additional indications.

Pipeline Products:Clinical-stage programs targeting hematological malignancies, solid tumors, and autoimmune diseases.

Specialties

CAR T Cell Therapy Chimeric Antigen Receptors Advanced Cell Programming T Cell Manufacturing Hematological Malignancies Solid Tumors Autoimmune Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 350000000 MR: - FA: $350 million FAN: 350000000	D: 2024-02-08 FD: 2024-02-08	6 investors
2	RT: Equity T: - FT: Equity	A: 163900000 MR: - FA: 163.9 million FAN: 163900000	D: 2022-12-01 FD: 2022-12-01	-

Underwritten Offering Latest

2024-02-08

$350.0M

6 investors (Pro only)

Equity 2022-12-01

$163.9M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News